TERT and neoplasm: Therapeutic treatments that target telomerase in tumours have been challenging (Gao & Pickett, 2022; Guterres & Villanueva, 2020), as some healthy somatic cells express very low levels of telomerase activity (e.g. lymphocytes) and key components of telomerase (e.g. TERT/TERC) are ubiquitously expressed.